Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
Sign Up to like & getrecommendations! Published in 2017 at "American Journal of Hematology"
DOI: 10.1002/ajh.24568
Abstract: Phosphatidylinositol‐3‐kinase (PI3K) signaling plays a crucial role in oncogene‐mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan‐class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT)… read more here.
Keywords: phase; pi3k; buparlisib; day ... See more keywords
The efficacy and safety of neoadjuvant buparlisib for breast cancer
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000017614
Abstract: Abstract Introduction: The efficacy of neoadjuvant buparlisib for breast cancer remains controversial. We conduct a systematic review and meta-analysis to explore the influence of neoadjuvant buparlisib versus placebo for breast cancer. Methods: We search PubMed,… read more here.
Keywords: breast cancer; efficacy; neoadjuvant buparlisib; buparlisib ... See more keywords
Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000672
Abstract: Background Glioblastoma relapse is associated with activation of phosphatidylinositol 3-kinase (PI3K) signalling pathway. In preclinical studies, the pan-PI3K inhibitor buparlisib showed antitumour activity in glioma models. Methods This was a two-part, multicentre, phase Ib/II study… read more here.
Keywords: phase; buparlisib; plus carboplatin; carboplatin lomustine ... See more keywords
The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23084295
Abstract: The aberrant activation of the phosphoinositide 3-kinase (PI3K)/ protein kinase B (AKT) pathway is common in pancreatic ductal adenocarcinomas (PDAC). The application of inhibitors against PI3K and AKT has been considered as a therapeutic option.… read more here.
Keywords: cell; pi3k akt; akt pathway; pathway inhibitors ... See more keywords